How to Select a Bioanalytical Laboratory for Clinical Development

Start by defining the analytical need

Laboratories specialize. A lab with deep small-molecule LC-MS/MS experience may have little ligand-binding capacity, and a strong immunogenicity group may sit in a different building, or company, from the PK team. Write down what you need before you talk to anyone.

Assay types and the main questions they raise
Assay type	Typical platforms	Regulatory framing	Key selection questions
Drug and metabolite concentrations (PK/TK)	LC-MS/MS (small molecules, many peptides and oligonucleotides); ligand-binding assays (most biologics)	ICH M10 ^[1]	Is there an existing method? Required sensitivity? Matrix? Metabolites to measure?
Anti-drug antibodies and neutralizing antibodies	Bridging immunoassays; cell-based or competitive ligand-binding NAb assays	FDA immunogenicity assay guidance for therapeutic protein products (2019); outside M10’s scope ^[3] ^[1]	Tiered screening, confirmation and titer strategy? Drug tolerance? Positive control availability?
Biomarkers	Immunoassays, LC-MS/MS, flow cytometry, molecular methods	FDA biomarker method validation guidance (2026); fit for purpose ^[2]	Will the data support regulatory decisions or internal decisions only? Reference material? Endogenous levels?

Method development and validation

The single biggest driver of timeline and cost is whether a usable method exists. Ask early whether the laboratory has validated a method for your molecule or a close analogue, whether you will own the method, and what transfer from a previous laboratory would involve.

Full validation for regulated studies. M10 expects full validation of methods used for nonclinical toxicokinetic studies under GLP, nonclinical PK studies conducted as surrogates for clinical studies, and all phases of clinical trials, in the primary matrix ^[1].
Platform-specific competence. M10 has separate chapters for chromatographic and ligand-binding assays, covering topics such as critical reagents, dilution linearity and the hook effect for ligand-binding assays, and reinjection reproducibility for chromatography ^[1]. Ask the laboratory to walk through how it handles these for an assay like yours.
Partial and cross validation. Changing laboratories, sites or method versions during a program requires partial or cross validation ^[1]. If you may move work later, agree the data and documentation you will receive now.
Biomarkers are fit for purpose. FDA’s biomarker guidance expects full validation where biomarker data support regulatory decisions, such as pivotal safety or efficacy or labeled dosing, while assays for internal decisions can be validated to the extent the sponsor judges appropriate. It treats parallelism and the effects of sample handling and shipping as key characteristics ^[2].

Sample logistics and chain of custody

Many bioanalytical problems begin before the sample reaches the laboratory. Stability, shipping conditions and documentation errors can invalidate otherwise good assays, and biomarker stability under sample handling and shipping is called out explicitly in FDA’s biomarker guidance ^[2].

Checklist

Logistics to settle before first sample

Collection, processing and storage instructions in the lab manual, aligned with validated stability
Who supplies collection kits, and lead times for kit production
Shipping conditions, couriers, and import or export permits for each country
Sample receipt reconciliation against the manifest, and how discrepancies are resolved
Long-term storage conditions, temperature monitoring and alarm response
Retention, return or destruction of samples at study end, and consent constraints on future use
Chain-of-custody documentation available for audit

Quality requirements and data integrity

Clinical sample analysis is conducted under GCP expectations; GLP regulations govern nonclinical laboratory studies supporting safety ^[1] ^[5]. A laboratory may cite GLP, GCLP, CLIA or ISO/IEC 17025. These are different things: FDA does not certify GLP compliance but inspects facilities, while some national GLP monitoring authorities outside the US issue compliance statements; GCLP is a published framework, not a regulation; a US CLIA certificate is needed where results are reported for individual patient diagnosis, treatment or health assessment, which research PK concentrations usually are not; and ISO/IEC 17025 is an accreditation for specific tests. Treat each as relevant only where it applies to your study type, and ask for the scope of any certificate or accreditation rather than accepting a logo.

The sponsor remains responsible for activities it transfers to a service provider. ICH E6(R3) expects sponsors to assess a provider’s suitability before selection, to have access to its relevant procedures and performance information, and to oversee subcontracted work ^[4]. Where a laboratory also performs GMP testing, such as release or stability testing of clinical supplies, FDA’s quality agreement guidance is a useful model (it is written for commercial manufacturing, but FDA says its principles can be applied to clinical trial materials), and it includes a scenario in which an owner failed to audit a contract laboratory that reported false passing results ^[7].

FDA’s data integrity question-and-answer guidance was written for drug CGMP records, and the MHRA’s GxP data integrity guidance for regulated records more broadly; their questions make a practical checklist for any laboratory producing data you will rely on ^[8] ^[9].

Questions to ask

Data integrity questions

1.Are chromatography and plate-reader systems validated, with audit trails enabled and reviewed? Who reviews them, and how often? ^[8]
2.How are reintegrations and reanalyses controlled, justified and documented?
3.Are user accounts individual, with no shared logins? ^[8]
4.What is the original record for each instrument type, and is dynamic electronic data retained rather than printouts? ^[8]
5.Which electronic systems hold regulated records, and how do they meet Part 11 controls? ^[6]
6.What data and metadata do you deliver with the bioanalytical report, and can we access raw data on request? ^[9]

Capacity and turnaround

Turnaround commitments matter most where PK data gate dose escalation or the next cohort. Ask for turnaround from sample receipt to reported concentrations for each study, the instrument and staff capacity behind it, and how the laboratory prioritizes when several sponsors need results in the same week.

Instrument time and analyst capacity for your platform specifically, not the laboratory overall
Turnaround for method validation, for routine batches and for urgent dose-escalation batches
Sample storage capacity at the required temperatures
Back-up plans for instrument failure
The format and timing of data transfers to your PK analyst or biometrics provider

The data transfer to your PK or biometrics team is a frequent friction point. Agree a data transfer specification early; see the clinical biometrics guide for the downstream requirements.

Compare cost and scope like for like

Bioanalytical cost drivers to normalize across proposals
Item	What to check
Method development or transfer	Fixed fee or time and materials; what happens if development fails
Validation	Full or partial; the experiments included; stability durations; validation report
Sample analysis	Price per sample and assumptions on runs, repeats and failed batches
Incurred sample reanalysis	Included, and at what percentage
Critical reagents	Who sources and pays for antibodies, reference standards and controls
Storage and shipping	Monthly storage fees, kit costs, courier and import charges
Reporting and data transfers	Number of reports and transfers included
Investigations	How failed runs, investigations and ISR failures are charged

Questions to ask the laboratory

Questions to ask

Qualification questions

1.Have you validated a method for this molecule, or a similar one, and can you share a redacted validation summary?
2.Which version of which guidance will you validate against, and why? ^[1]
3.Who are the scientific lead and the study director or principal investigator, and what is their experience with this assay type?
4.What is your capacity on this platform over the next twelve months?
5.How many runs fail, and how many ISR assessments fail, for comparable assays?
6.Which work, if any, is subcontracted or performed at another site?
7.When were you last inspected by a regulator or audited by a sponsor for comparable work, and what were the findings?
8.How will you handle samples from multiple countries, including import permits?
9.What data, metadata and documentation will we receive, in what format?

Red flags

Validation plans with no reference to the applicable guidance, or that treat biomarker or ADA assays as if M10 applied unchanged
No incurred sample reanalysis in a proposal for a study where M10 expects it
Vague answers about which site performs the work
Reluctance to discuss failed runs, ISR failures or inspection outcomes
Price per sample far below peers, with exclusions for repeats and reagents
Shared instrument logins or audit trails that are “available if needed” but never reviewed

What to include in a bioanalytical RFP